Flashpoint Therapeutics brings a new approach to designing cancer immunotherapies that transform therapeutic components from ineffective to curative through optimized nanoscale architecture. The company's nanotechnology-based discovery platform enables more potent multi-targeted therapies by co-delivering diverse RNA, DNA, and peptide cargo to the right cells with precise control of stoichiometry, optimized structure-function relationship and synchronized activation kinetics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/25/23 | $10,000,000 | Seed |
Beta Lab CS Ventures | undisclosed |
